Vir Biotechnology CEO Executes Routine Sale of Equity Stake

Marianne De Backer, President and CEO of Vir Biotechnology, Inc., sold 72,559 shares of company stock on April 6, 2026. According to an SEC Form 4 filing, the transaction was executed at a price of $9.16 per share, resulting in a total transaction value of approximately $664,000. This disposal represents a small fraction of De Backer's total equity, as she retains over 90% of her holdings. The sale is consistent with a pattern of periodic disposals observed in recent years and does not appear to signal a strategic exit from the investment. Despite the insider sale, Vir Biotechnology continues to report positive operational momentum. The company recently announced encouraging results from a Phase 1 trial of VIR-5500, a therapy targeting advanced-stage prostate cancer. In one of the higher-dose groups, 82% of patients experienced a reduction in prostate-specific antigen (PSA) levels by at least half. Further supporting the company's financial position is a co-development and co-commercialization agreement with Astellas Pharma. Under the terms of the deal, Astellas has provided Vir with $240 million in cash and a $75 million equity investment. Astellas will lead the commercialization of VIR-5500 in the U.S. market if the treatment receives approval, while Vir will be responsible for 40% of development costs and eligible for double-digit royalties on non-U.S. sales.